medigraphic.com

2006, Number 2

<< Back Next >>

Rev Mex Anest 2006; 29 (2)

Response to treatment for painful diabetic neuropathy

Betancourt-Sandoval JA, Guevara-López U, Covarrubias-Gómez A, Delgado-Carlo MM, Hernández-Martínez JR, Cardona-Cordero AV

Language: Spanish
References: 41
Page: 74-79
PDF size: 105.55 Kb.


ABSTRACT

Objective: To assess the response to treatment for painful diabetic neuropathy in outpatients at a pain clinic, from January 1999 through December 2003. Materials and methods: A descriptive, retrospective study of the medical files of 158 patients with diabetic neuropathy; 39 of them were excluded for various reasons. The response to treatment was assessed using an visual analogue scale (VAS), comparing the grades at the beginning, middle and end of the treatment. A correlation was also made with the drugs used for treatment. Results: Significant differences were observed between the response at the middle and the end of treatment compared to the beginning (p ‹ 0.05), as well as with all the drugs used for treatment (p ‹ 0.05). However, no significant differences were observed between drugs. Discussion: The findings suggest that all the drugs used were effective for the treatment of diabetic neuropathy, achieving varying degrees of pain control.


REFERENCES

  1. Aguilar-Rebolledo F. Neuropatía Diabética. 2ª edición, Editorial Distribuidora y Editora Mexicana S.A. de C.V. México. 2000:1,47.

  2. Yung MJ, Boulton AJM, Macleod AF. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetology 1993;36: 150-154.

  3. Vinik AI, Park TS, Stansberry KB. Diabetic neuropathies. Diabetology 2000;43:957-973.

  4. Diabetes control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.

  5. Kenneth E, Schmader R. Epidemiology and impact in quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-354.

  6. Partanen J, Niskanen L, Lehtinen J. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:89-94.

  7. Spruce J, Potter DV. The pathogenesis and management of painful diabetic neuropathy. Diabet Med 2003;20:88-98.

  8. Boulton AJM, Gries FA, Jervell J. Guidelines for the diagnosis and out patient management of diabetic peripheral neuropathy. Diabet Med 1998;15:917-931.

  9. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999;7:245-252.

  10. Thomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997;46(Suppl. 2): 554-557.

  11. Andrew JM, Boulton AJM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-1486.

  12. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health-Syst Phar 2004;61:160-176.

  13. Clarck CM, Lee DA. Prevention and treatment of diabetic neuropathy. Pharmacotherapy 1994;14:689-607.

  14. Gill JS. The efficacy of aldose reductase inhibitor, ponalrestat on diabetic neuropathy. Diabetes Metab 1990;16:246-302.

  15. Van Gerven JM. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insuline treatment and pancreatic transplantation. Drugs Aging 1995;6:9-28.

  16. Simons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol 2002;15:595-603.

  17. Eisenberg E, Lurie Y, Braker C. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505-509.

  18. Rosner H, Rubin L, Kestenbaum A. Gabapentine adjunctive therapy in neuropathic pain states. Clin J Pain 1996;12:56-58.

  19. Morello CM, Leckbraund SG, Stoner CP. Effect of gabapentin compared to amitriptyline on pain in diabetic peripheral neuropathy. Diabetes 1998;47:134.

  20. Gómez-Prez FJ, Hoza R, Rios JM. Nortriptyline fluphenazine vs carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996;27:525-529.

  21. Collins SL, Moore A, McQuay HJ, Wiffen P. Anti-depressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systemic review. J Pain Symptom Manag 2000;20:449-458.

  22. Edwards K, Glantz MJ, Button J. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind placebo-controlled study. Neurology 2000:S4:81.

  23. Lacobellis D, Allen R, Lamoreaux L. A double-blind, placebo-control trial of pregabalin for the treatment of painful diabetic peripheral neuropathy. Neurology 2000;S4:177.

  24. Kastrup J, Petersen P, Dejard A, Angelo H, Hilstead J. Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy. Pain 1987;28:69-75.

  25. Jarvis B, Couked AJ. Mexiletine a review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.

  26. Newton WP, Collins L. What is best treatment for diabetic neuropathy? J Fam Pract 2004;53:403-407.

  27. Harati Y, Gooch C, Swenson M. Double-blind randomized trial tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-1846.

  28. Nelson KA, Park KM, Robinovitz E. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-1218.

  29. Max MB, Lynch SA, Muir J, Shaof SE, Smoller B, Dubner R. Effects of desipramine, amitriptiline and fluoxetine on pain relief in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.

  30. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for the management of pain: a systematic review. BMJ 1995;311:1047-1052.

  31. Boulton AJM. Current and emerging treatments for the diabetic neuropathies. Diabetes Rev 1999;7:279-386.

  32. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofaldo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-1836.

  33. Rosenstok J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-638.

  34. Sharma U, Iacobellis D, Glessner C, Moore J, Yung JP, LaMoreaux L, Poole RM. Pregabalin effectively relieves pain in two studies with painful diabetic peripheral neuropathy. Am Pain Soc Atlanta, 2000.

  35. Beydoun A, Kobetz SK, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004;20:174-178.

  36. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-918.

  37. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Metab 1977;3:97-107.

  38. Zieglar D, Gries FA, Spuler M. The epidemiology of diabetic neuropathy. J Diabetes Comp 1992;6:49-57.

  39. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853.

  40. Adler AI, Boyko EJ, Ahroni JH. Risk factors for diabetic peripheral sensory neuropathy. Diabet Care 1997;20:1162-1167.

  41. Ziegler D. Cardiovascular autonomic neuropathy: Clinical manifestations and measurement. Diabetes Rev 1999;7:342-357.




2020     |     www.medigraphic.com